Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Regina Sanders

Registered Nurse, Psychiatric/Mental Health Springfield, MA Nurse Practitioner

NPI 1477615334 CMS profile 10945213

417 Liberty St, Springfield, MA 01104

Open in the dashboard

General payments

$2,280

94 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Regina Sanders of Springfield, MA is reported in the CMS Open Payments database as having received $2,280 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Registered Nurse, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $180 5
2022 General $1,404 53
2021 General $696 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Regina Sanders
  • Registered Nurse, Psychiatric/Mental Health median
  • Middle half of Registered Nurse, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Regina Sanders were reported at $0. Among 280 Registered Nurse, Psychiatric/Mental Health profiles paid that year, the median was $140 and the middle half received between $43 and $515.

Show as a table
Year Regina Sanders Registered Nurse, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $696 $101 $31–$244 $132
2022 $1,404 $103 $36–$248 $149
2023 $180 $138 $45–$382 $160
2024 $0 $167 $39–$462 $164
2025 $0 $140 $43–$515 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Neurocrine Biosciences, Inc. $573 13 payments
  2. Otsuka America Pharmaceutical, Inc. $407 19 payments
  3. Sunovion Pharmaceuticals Inc. $403 21 payments
  4. AbbVie, Inc. $302 16 payments
  5. ITI, Inc. $260 9 payments
  6. Lundbeck LLC $79 3 payments
  7. Janssen Pharmaceuticals, Inc $75 5 payments
  8. Teva Pharmaceuticals USA, Inc. $67 2 payments
  9. Alkermes, Inc. $66 4 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $27 1 payment
  11. Other $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,280 94 payments
Products named General payments · program years 2021–2023
  1. INGREZZA Neuropsychiatry $462 8 payments
  2. LATUDA $403 21 payments
  3. REXULTI Psychiatry $304 17 payments
  4. VRAYLAR $302 16 payments
  5. CAPLYTA $260 9 payments
  6. INGREZZA Neurology $112 5 payments
  7. ABILIFY MAINTENA $103 2 payments
  8. REXULTI Psychiatry $79 3 payments
  9. INVEGA SUSTENNA $75 5 payments
  10. AUSTEDO $67 2 payments
  11. Other $425 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,855

Median for Nurse Practitioner: 389

Drug cost

$333,339

Median for Nurse Practitioner: $21,885

Branded share of claims

24.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 12 $92,902
Trintellix Vortioxetine Hydrobromide Brand 54 $48,514
Caplyta Lumateperone Tosylate Brand 26 $48,376
Lurasidone Hcl Generic 44 $24,187
Vraylar Cariprazine Hcl Brand 13 $20,907
Rexulti Brexpiprazole Brand 12 $20,076
Lybalvi Olanzapine/Samidorphan Malate Brand 11 $17,454
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 147 $6,999
Bupropion Xl Bupropion Hcl Brand 185 $5,098
Quetiapine Fumarate Generic 179 $4,097

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$31,290

Medicare's payments for the services billed

Medicare patients

77

Average age 56

Services billed

440

50 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 62%
High blood pressure 47%
Arthritis 38%
COPD 29%
Diabetes 26%
Chronic kidney disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record